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Purpose: The aim of this study was to investigate disease onset and disease progression in 
patients with severe chronic central serous chorioretinopathy (cCSC).
Patients and methods: The medical records of 143 cCSC patients (199 eyes) were reviewed. 
All cases had visual complaints for .6 months and showed signs of a severe disease phenotype 
on optical coherence tomography (OCT) and fluorescein angiography (FA). Clinical presenta-
tion at onset was evaluated, together with disease progression on multimodal imaging and final 
treatment outcome.
Results: Twenty-eight cases (14%) had a documented history of an acute episode of CSC, 
whereas 145 cases (73%) showed pre-existing features of chronicity already at first presentation. 
The first clinical presentation could not be evaluated in 13% of cases. Best-corrected visual 
acuity (BCVA) was 70 ± 18 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters 
at onset and 70 ± 22 ETDRS letters at final visit (p = 0.770). Among all studied cases, 173 eyes 
(87%) were treated, which resulted in complete resolution of subretinal fluid (SRF) in 76% of 
eyes at final visit. In eyes with fluorescein angiographic follow-up, the area of diffuse atrophic 
retinal pigment epithelium (RPE) abnormalities (diffuse atrophic RPE alterations [DARA]) had 
increased significantly in 43 eyes (68%) at final visit.
Conclusion: CSC encompasses a clinical spectrum that includes a range of severe phenotypes, in 
which retinal abnormalities tend to be progressive. Nevertheless, the long-term visual acuity may 
remain fairly stable with treatment. Few patients with severe chronic CSC have a history of acute CSC, 
which could indicate that there may be pathogenetic differences between these 2 CSC variants.
Keywords: chronic central serous chorioretinopathy, long-term outcome, severity, treatment, 
photodynamic therapy, posterior cystoid retinal degeneration
Introduction
Central serous chorioretinopathy (CSC) is characterized by a serous detachment of the 
neurosensory retina.1 Although the precise pathophysiology of CSC is unclear, a con-
gested and hyperpermeable choriocapillaris and thickened choroid (pachychoroid) may 
be the primary source of serous fluid leakage.2 Additionally, it is hypothesized that due 
to secondary retinal pigment epithelium (RPE) alterations, the outer blood–retinal barrier 
is dysfunctional, which subsequently leads to fluid passage into the subretinal space.3 
A prolonged presence of subretinal fluid (SRF) can lead to irreversible photoreceptor 
damage and dysfunction,4 resulting in visual complaints such as blurry vision, metamor-
phopsia, dyschromatopsia, micropsia, macropsia, and disturbed contrast vision. Men in 
the professional age range are affected most frequently.5 Thus far, the most important 
identified risk factors include the use of corticosteroids, endogenous hypercortisolism, 
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mental stress, and pregnancy.6 Genetic risk factors have also 
been shown to be associated with CSC.7–9
Although there is no generally accepted classification of 
CSC, 2 basic forms of CSC are often distinguished: acute 
and chronic CSC (cCSC).4,10 The acute phenotype of CSC is 
typically defined as an acute episode of central vision loss due 
to SRF leakage, with a single “hot spot” of leakage through 
the RPE seen on fluorescein angiography (FA), without any 
atrophic RPE abnormalities. In this definition, acute CSC is 
generally self-limiting, with spontaneous resolution within 
3–6 months after onset and a favorable visual prognosis.10 In 
contrast, patients with cCSC do not tend to have a spontaneous 
resolution of SRF, have a more unfavorable visual prognosis,11 
and a variable clinical manifestation.10 Some patients with 
cCSC may present with relatively limited atrophic RPE altera-
tions, focal RPE detachments, and focal leakage.
There are other cases that show more severe forms of 
cCSC. They show widespread areas of RPE atrophy, larger 
and more numerous RPE detachments, diffuse areas of leak-
age through the RPE, and posterior cystoid retinal degenera-
tion (PCRD), and in rare cases even inferior bullous retinal 
detachments are present.12–14 In the past, the term diffuse 
retinal pigment epitheliopathy has also been used to distin-
guish this severe disease course from more acute forms of 
CSC.15 Little is known about the clinical characteristics, the 
long-term outcome, and response to treatment in these severe 
cases of cCSC. Also, it is unclear whether severe cases of 
cCSC are generally preceded by previous episodes of typical 
acute CSC. As a consequence, there is currently an ongoing 
debate on whether acute CSC and (severe) cCSC are either 
part of a clinical and pathophysiological continuous spec-
trum, or if these phenotypes are more distinct with regard to 
their background, presentation, and treatment outcome.
In the present study, we describe a large group of cCSC 
cases that show phenotypic signs of severity. The aim of 
the study was to describe the range of clinical findings on 
multimodal imaging in these presumably severe cCSC cases 
and to evaluate the long-term visual outcome and treatment 
response. Finally, we assess whether or not these severe 
cCSC cases were preceded by typical acute CSC.
Patients and methods
Patient selection
In this retrospective multicenter study, patients were included 
from 3 Dutch tertiary referral centers: the Department of Oph-
thalmology of Leiden University Medical Center (Leiden, 
the Netherlands), the Rotterdam Eye Hospital (Rotterdam, 
the Netherlands), and the Department of Ophthalmology 
of Radboud University Medical Center (Nijmegen, the 
Netherlands). Study patients were selected from a cohort 
of 1,387 subjects who were diagnosed with acute CSC and 
cCSC between 2005 and 2016. For the purpose of this study, 
we only included cCSC. Chronicity was defined as persis-
tence of visual complaints for .6 months, in the presence 
of anatomical abnormalities compatible with typical chronic 
CSC,8 such as multifocal diffuse RPE alterations and chronic 
SRF leakage based on multimodal imaging that included opti-
cal coherence tomography (OCT), FA, and/or indocyanine 
green angiography (ICGA). In addition, a cCSC case was 
considered severe when at least 1 of the following abnor-
malities within the anatomical macular area inside the largest 
temporal vascular arcades (Figure 1) was present: 1) cumula-
tive areas of .5 optic disc diameters (DD) of diffuse atrophic 
RPE alterations (DARA) as visualized on mid-phase FA; 2) at 
least 2 “hot spots” of leakage separated by at least 1 DD of 
non-hyperfluorescent healthy-appearing retina on mid-phase 
FA (multifocal “hot spots”); 3) an area of diffuse fluorescein 
leakage with a surface of .1 DD on mid-phase FA, without 
an evident leaking focus (diffuse leakage); and 4) presence 
of PCRD assessed on OCT.12 All included cases had to have 
at least 1 of these severe criteria, but could have up to all 4 
criteria. Subjects were excluded when there was a suspicion 
of a (secondary) choroidal neovascularization and/or poly-
poidal choroidal vasculopathy or in the case of evidence of 
other underlying retinal diseases such as age-related macular 
degeneration (with presence of drusen in both eyes), multifo-
cal choroiditis, retinal vascular occlusions, pseudoxanthoma 
elasticum, amblyopia, or high myopia (.6 diopters).
Clinical outcome measures
Retrospective data were collected on the patient’s first presen-
tation, based on available multimodal imaging (at least FA and 
OCT). This information was used to distinguish between an 
acute and a chronic first manifestation of CSC. RPE detach-
ments outside the area of SRF leakage, evidence of RPE 
atrophy (visible as window defects on FA), and/or multifocal 
hot spots or diffuse fluorescein leakage were seen as signs of 
chronicity. In contrast, a presentation with one well-defined 
pinpoint leakage on FA, lack of any RPE alterations, and a 
sudden neurosensory detachment followed by a spontaneous 
recovery in ,6 months were considered to represent a typical 
acute CSC episode. In case no images at first presentation were 
available, the clinical description by the treating ophthalmolo-
gist was used to distinguish between an acute and a chronic first 
presentation. Furthermore, information was collected on all 
treatment strategies and treatment response, the progression of 
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atrophic retinal abnormalities, and visual acuity at presentation 
(baseline), and at last available follow-up visit (final follow-up). 
Information on the use of steroid-containing medication and 
endogenous hypercortisolism was collected. The extent of 
atrophic retinal abnormalities as DARA surface was quanti-
fied on FA images by using the available caliper measurement 
tools on FA equipment and expressed in number of DD. The 
location of DARA was identified and categorized as follows: 
1) including the fovea, 2) within 1 DD of the fovea, but sparing 
the fovea, and 3) .1 DD outside the fovea. The location of hot 
spots of leakage on FA was described as either inside or outside 
the largest temporal retinal vascular arcade. Central foveal 
thickness (CFT) was measured manually in patients in whom 
a spectral-domain OCT was available. CFT was defined as 
the distance from the inner border of the internal limiting 
membrane (ILM) to the inner border of the ellipsoid zone 
(EZ) to minimize measurement errors due to the presence of 
subretinal accumulation of debris and SRF in active cCSC. 
CFT was evaluated at the moment of diagnosis of severe cCSC 
and compared to the final visit.
Clinical examinations
All patients underwent a range of ophthalmological and mul-
timodal imaging examinations at the moment of diagnosis and 
during follow-up. This included best-corrected visual acuity 
(BCVA) (measured with Snellen charts, which was converted 
to Early Treatment of Diabetic Retinopathy Study (ETDRS) 
letters for statistical comparisons),16 slit lamp examination, 
and/or color fundus photography (either Topcon Corp., Tokyo, 
Japan or Carl Zeiss Meditec AG, Jena, Germany), either time-
domain OCT (either Cirrus HD-OCT; Carl Zeiss Meditec AG, 
or OCT-HS100; Canon Inc, Tokyo, Japan) or spectral-domain 
OCT (Spectralis HRA + OCT; Heidelberg Engineering, 
Heidelberg, Germany), FA (Heidelberg Engineering, Topcon 
Figure 1 illustration of the 4 criteria of severity on Fa and OCT. 
Notes: The 4 criteria are as follows: 1) cumulative areas of .5 DD of diffuse atrophic retinal pigment epithelium alterations as visualized on mid-phase Fa (A). 2) Multiple 
(at least 2) “hot spots” of leakage separated by at least 1 DD of non-hyperfluorescent healthy-appearing retina on mid-phase FA (B). 3) An area of diffuse fluorescein leakage 
with a surface of .1 DD on mid-phase Fa, without an evident leaking focus (C). 4) Presence of posterior cystoid retinal degeneration on OCT (D and E).
Abbreviations: DD, optic disc diameters; FA, fluorescein angiography; OCT, optical coherence tomography.
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Corp., or Carl Zeiss Meditec AG), and ICGA (Spectralis HRA 
+ OCT; either Topcon Corp or Carl Zeiss Meditec AG).
Treatment
In this retrospective study, the decision for treatment, retreat-
ment, and treatment modality was based on the preference 
of the treating ophthalmologist. Treatment was applied when 
there was persistent SRF affecting vision. Photodynamic 
therapy (PDT) was performed with different settings such as 
half-dose (3 mg/m2 verteporfin [Visudyne®; Novartis interna-
tional AG, Basel, Switzerland]), half-time (treatment dura-
tion of 42 seconds), half-fluency (25 J/cm2), or the original 
settings (6 mg/m2 verteporfin, 83 seconds, and 50 J/cm2) as 
described for neovascular age-related macular degeneration. 
Other reviewed treatments included subthreshold micropulse 
diode laser (SML) and conventional thermal laser.
statistical analysis
Statistical analysis was performed using IBM SPSS software 
for Windows, version 23 (IBM Corporation, Armonk, 
NY, USA). Either a paired samples t-test or a one-way 
analysis of variance (ANOVA) test was used for comparing 
mean values in continuous numerical data. Categorical data 
were analyzed using either a Chi-square test or a McNemar 
Chi-square test. Multivariate regression analyses were per-
formed using a forward stepwise linear regression, where the 
final BCVA outcome was used as a dependent variable and 
multiple-associated clinical findings (as will be described 
later on) as explanatory variables. The best linear model for 
grading of discrepancy decrease was calculated. A p-value of 
,0.05 was considered significant in all performed tests.
ethics approval
All procedures performed in this study involving human partici-
pants were in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the 1964 
Declaration of Helsinki and its later amendments or comparable 
ethical standards. The local institutional review boards in all 
participating centers (‘Medisch Ethische Toetsingscommissie’ 
(METC) in Leiden University Medical Center, The METC in 
the Radboud University Medical Center, and the ‘Wetenschap-
scommissie’ in the Rotterdam Eye Hospital) did not require 
written consent from the participants for reviewing their medical 
records, as all data were anonymized upon collection.
Results
After a review of the medical charts and clinical characteris-
tics on multimodal imaging, a total of 143 patients (199 eyes, 
87% males, 83% Caucasians) with cCSC could be included 
who met our definition of severity in at least 1 eye. Mean age 
at diagnosis of CSC was 46 years, and mean follow-up dura-
tion was 7.5 years (Table 1). At final follow-up, 56 patients 
(39%) had a severe cCSC phenotype in both eyes. Severity 
manifested on average after 5.6 months (0–94 months) in 
the second eye in this subgroup. After reviewing data on the 
very first presentation of CSC, 28 eyes (14%) started with 
an acute episode with limited or no RPE damage and spon-
taneous resolution of SRF. However, most of the included 
subjects (145 eyes, 73%) already showed a chronic phenotype 
at first presentation, with $1 significant multifocal areas of 
atrophic RPE alterations and/or multifocal areas of leakage. 
In 26 eyes (13%), insufficient information from the primary 
disease manifestation was available.
Characteristics on multimodal imaging
In 133 eyes (67%), .1 criterion of severity was present at some 
point during the follow-up. The distribution of these criteria of 
severity is summarized in Table 2. A gravitational tract was 
observed in 84 eyes (42%) on FA. Fifteen eyes (8%) had a 
secondary macular epiretinal membrane without evidence of 
diseases other than CSC explaining the membrane. Fundus 
photography, OCT, and FA revealed choroidal folds in 3 eyes 
(2%), without a hyperopic refractive error. Hard exudates 
were observed in 6 eyes (3%) without any sign of retinal (neo)
vascular abnormalities or polypoidal choroidal vasculopathy 
on FA and ICGA. In 1 patient (1 eye, 0.5%), a bullous inferior 
retinal detachment secondary to cCSC was present (Figure 2). 
ICGA images were available in 134 of the studied eyes (67%). 
When comparing the cumulative area of hyperfluorescent RPE 
alterations and leakage on FA with the area(s) of hyperfluo-
rescent choroidal hyperpermeability on ICGA in these 134 
eyes, the cumulative area of abnormalities was larger on ICGA 
as compared to FA in 79 eyes (59%, 79/134), whereas in 50 
eyes (37%, 50/134) these areas were equal in size. A smaller 
Table 1 Patient demographics
Characteristics Cases
Patients (eyes) 143 (199)
Male gender, n (%) 121 (87)
Caucasian ethnicity, n (%) 119 (83)
Mean age at diagnosis of CsC (range) 46 (26–78)
Mean available follow-upa in years (range) 7.5 (0.3–30.6)
Patients with recentb use of steroids, n (%) 25c (18)
BCVA at first presentation (ETDRS letters) 70 ± 18
Notes: aThe mean time from CSC diagnosis to final visit. bWithin 3 months prior to 
diagnosis. cOne patient was diagnosed with Cushing syndrome. Data presented as 
mean ± sD unless otherwise indicated.
Abbreviations: BCVa, best-corrected visual acuity; CsC, central serous 
chorioretinopathy; eTDrs, early Treatment of Diabetic retinopathy study.
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cumulative area of hyperfluorescent abnormalities on ICGA as 
compared to FA was present in only 5 eyes (4%, 5/134).
BCVa
Mean BCVA in this cohort was 70 (±18) ETDRS letters at first 
presentation (baseline BCVA). BCVA at the moment of diag-
nosis of severe cCSC, on average 4 years after first presenta-
tion, was 68 (±19) ETDRS letters. The final mean BCVA, on 
average 5.2 years (range: 0.1–25 years, median = 2.8 years) 
after first presentation, was 70 (±22) ETDRS letters, which 
was not statistically different in comparison with baseline 
(paired samples t-test, p = 0.770) and with the moment of 
diagnosis of severe CSC (p = 0.061) (Table 3). Among 
clinical characteristics (Table 4), final BCVA correlated 
most significantly with the location of DARA in the macula 
(r = 0.4, Pearson correlation, p , 0.001) (Table 4). Mean 
final BCVA in eyes showing DARA with foveal involvement 
was significantly worse (63 ± 22 ETDRS letters) compared 
to both eyes with DARA located within 1 DD of the fovea – 
but excluding the fovea (74 ± 19 ETDRS letters, one-way 
ANOVA, p = 0.003) and eyes with DARA outside 1 DD of 
the fovea (78 ± 18 ETDRS letters, p , 0.001). Mean final 
BCVA did not significantly differ among eyes with DARA 
located within 1 DD of the fovea – but excluding the fovea – 
compared to eyes with DARA .1 DD away from the fovea 
( p = 0.582). In 9 eyes (5%), a BCVA drop .2 ETDRS 
lines was observed after PDT with reduced settings. All of 
these eyes showed central DARA with foveal involvement. 
BCVA in 3 out of these 9 eyes (2%, 3/199) never recovered 
after PDT until final follow-up. In the first patient, BCVA 
had decreased from 83 to 70 ETDRS letters, in the second 
patient from 77 to 65 ETDRS letters, and in the third patient 
from 70 to 59 ETDRS letters. In 63 eyes (32%), evolution 
of DARA could be assessed on a second available FA, 
which was obtained on average 8 years (range: 1–27 years, 
median: 7 years) after the first FA images. In 43 of these eyes 
(68%, 43/63), the mean surface of DARA had increased on 
follow-up, from 6.5 DD to 10.3 DD (p , 0.001). In 20 eyes 
(32%, 20/63), DARA did not change as compared to the pre-
vious FA. A multiple linear regression model was computed 
to predict the final BCVA outcome based on the following 
parameters: baseline (before severity) BCVA, total area of 
DARA at first severe presentation, location of DARA, and 
presence of PCRD, which all correlated independently with 
final BCVA outcome. A significant regression equation was 
found (F(4, 167) = 36.967, p , 0.001) with an R2 of 0.470 
and an adjusted R2 of 0.457. According to this model, baseline 
BCVA, total area of DARA, location of DARA, and presence 
of PCRD explain up to 47% of the observed variance in final 
BCVA outcome in the present study.
Treatment and disease recurrence
In this cohort of severe cCSCs, 173 eyes (87%) were treated 
at least once (mean: 2.4 treatments, range: 1–20 treatments) 
from the diagnosis of CSC until final follow-up (Table 5). 
A majority of these eyes (83%, 143/173) were treated after 
the onset of severe disease. Eighty-one of these eyes (47%, 
81/173) were treated only once until the final visit. Of these, 
41 eyes (51%, 41/81) never experienced a recurrence after 
this single treatment. A complete resolution of SRF at final 
follow-up, on average 3.6 ± 4 years after disease onset, was 
seen in 72 eyes (89%, 72/81) in this subgroup. Treatment 
modality and the number of treatments varied widely among 
the severe cCSC cases (Table 5). Treatment efficacy, defined 
as a complete resolution of SRF and PCRD, was also highly 
variable among different treatment modalities (Table 5). 
In 173 of the 199 eyes (87%), there was SRF accumulation 
on OCT at the moment of first severe cCSC presentation. 
This presence of SRF was significantly less frequent at final 
visit (47 eyes [24%], McNemar test, p , 0.001). A com-
parable significant reduction from 35% (69 eyes) at severe 
presentation to 18% (35 eyes) at final visit was observed in 
the incidence of PCRD (Table 3). Throughout the follow-up 
period, 119 eyes (60%) had multiple SRF recurrences (mean: 
1.2 recurrences, range: 1–9 recurrences), whereas in 59 eyes 
(30%) no recurrence occurred. In 21 eyes (10%), there was 
insufficient information on disease recurrence.
Table 2 Distribution of each criterion of severity among the 
severe cases of chronic central serous chorioretinopathy
Criteria Frequency and specifications
eyes with Dara, n (%) 145 (73)
Mean Dara surface (DD) 8.6 ± 4
location of Dara, n (%) 75 (52) covering the fovea
47 (32) within 1 DD of the foveaa
23 (16) outside 1 DD of the fovea
eyes with PCrD, n (%) 69 (35)
eyes with multiple hot spots, n (%) 115 (58)
Mean number of hot spots (range) 3 (2–7)
location of hot spots, n (%) 88 (75) inside the temporal vascular 
arcade
3 (3) outside the temporal vascular 
arcade
26 (22) both inside and outside
eyes with diffuse leakage, n (%) 60 (30)
Notes: aDara surface overlaps with the area as wide as 1 DD around the fovea, 
but does not cover the foveal depression. Data presented as mean ± sD unless 
otherwise indicated.
Abbreviations: Dara, diffuse atrophic retinal pigment epithelium (rPe) alterations; 
DD, optic disc diameters; PCrD, posterior cystoid retinal degeneration.
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Figure 2 Clinical features on multimodal imaging of the right eye of a 44-year-old male patient with severe chronic central serous chorioretinopathy and a bullous inferior 
retinal detachment.
Notes: Color fundus photograph showed extensive retinal abnormalities in the macula, with multifocal areas of whitish fibrinous subretinal material (A). The white arrow 
shows the scanning plane which is depicted on the sD-OCT scans (D and E). Fa imaging (B) revealed multiple foci of leakage and widespread rPe alterations. The areas of 
hyperfluorescence on mid-phase ICGA (C) depicted diffuse choroidal hyperpermeability which is larger as compared to the abnormalities on Fa. an sD-OCT scan (D) at first 
presentation and prior to treatment revealed a subretinal srF accumulation, a subfoveal rPe detachment, and PCrD in the outer nuclear layer of the retina. at ∼4 months 
after half-dose PDT using a large spot size of 1,200 µm centered on the hyperfluorescent zones on ICGA, both SRF and intraretinal fluid on OCT had resolved completely (E). 
The choroid before treatment was markedly thickened (D). This choroidal thickness reduced after PDT but showed large cavities in the deep choroidal (haller) layers, with 
limited or no rPe damage and spontaneous resolution of srF layers (E).
Abbreviations: FA, fluorescein angiography; ICGA, indocyanine green angiography; PCRD, posterior cystoid retinal degeneration; PDT, photodynamic therapy; RPE, retinal 
pigment epithelium; SD-OCT, spectral-domain optical coherence tomography; SRF, subretinal fluid.
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Discussion
In this retrospective multicenter study, we assessed the 
clinical characteristics in a large series of eyes with a severe 
variant of cCSC, after suggesting a definition for severity. 
A majority of the studied eyes (73%) manifested pre-existing 
signs of chronicity at first disease presentation, where only 
14% started with a documented acute CSC episode. In con-
trast to a high percentage of SRF resolution, final visual 
outcome did not improve significantly after treatment in this 
cohort. The final visual outcome was strongly associated with 
baseline visual acuity, surface of DARA, and the presence 
of DARA within 1 DD of the fovea.
CSC is considered the fourth most common macular 
disease associated with SRF and/or intraretinal fluid leak-
age, after age-related macular degeneration, diabetic macular 
edema, and retinal vascular occlusions.4 A prolonged disease 
course in CSC is known to cause progressive visual decline 
and can lead to secondary choroidal neovascularization and/
or polypoidal choroidal vasculopathy.17–19 Although there is 
no consensus on the exact definition of chronicity, the most 
prevalent retinal and choroidal abnormalities characterizing 
Table 3 Characteristics at first presentation and disease progression in severe cases of chronic central serous chorioretinopathy
Characteristics Severe manifestation 
of CSC
Final follow-up 
visit
p-value
BCVa (eTDrs letters) 68 ± 19 70 ± 22 0.061
eyes with srF, n (%) 173 (87) 47 (24) ,0.001
eyes with PCrD, n (%) 69 (35) 35 (18) ,0.001
CFTa (µm) 105 ± 31 106 ± 30 0.930
Dara surfaceb (DD) 6.3 ± 3 9.0 ± 5 ,0.001
Mean number of treatmentsc (range) n/a 2.5 (1–20) n/a
Mean number of recurrencesd (range) n/a 1.2 (0–9) n/a
Notes: aCFT could be measured manually in 63 eyes (32%) with a spectral-domain optical coherence tomography. bin 68 cases (34%), a follow-up Fa (at least 1 year later) was 
available to be compared with baseline Fa. cTwenty-six cases (13%) were never treated and were not included in this analysis. dTwenty-one cases (11%) never showed a complete 
resolution of srF, and were not included in this analysis. Data presented as mean ± SD unless otherwise indicated. Bold font indicates data were considered statistically significant.
Abbreviations: BCVa, best-corrected visual acuity; CsC, central serous chorioretinopathy; CFT, central foveal thickness; Dara, diffuse atrophic retinal pigment epithelium 
(RPE) alterations; DD, optic disc diameters; ETDRS, Early Treatment of Diabetic Retinopathy Study; FA, fluorescein angiography; n/a, not applicable; PCRD, posterior cystoid 
retinal degeneration; SRF, subretinal fluid.
Table 4 Pearson correlation coefficients between patient 
characteristics and final visual outcome
Characteristics Correlation with BCVA 
outcome
r Evaluated 
cases
Multivariate 
p-value
Male gender 0.161 197 0.024
age at disease onset -0.086 197 0.225
Caucasian ethnicity -0.045 197 0.526
recent steroid use 0.042 197 0.551
Disease duration -0.105 197 0.143
Baseline BCVa 0.543 197 ,0.001
Presence of PCrD -0.297 195 ,0.001
Presence of multifocal hot spots 0.023 195 0.023
Mean number of hot spots -0.036 152 0.656
location of multifocal hot spots -0.036 154 0.657
Presence of diffuse leakage -0.163 195 0.023
Presence of Dara -0.265 197 ,0.001
surface of Dara -0.343 197 ,0.001
location of Dara 0.400 197 ,0.001
Dara involving the fovea -0.386 197 ,0.001
Dara within 1 DD of the 
fovea, but sparing the fovea
0.128 197 0.072
Dara more than 1 DD  
outside the fovea
0.309 197 ,0.001
Mean number of recurrences -0.063 176 0.409
Notes: r, correlation coefficient. Bold font indicates data were considered statistically 
significant.
Abbreviations: BCVa, best-corrected visual acuity; Dara, diffuse atrophic retinal 
pigment epithelium (rPe) alterations; DD, optic disc diameter; PCrD, posterior 
cystoid retinal degeneration.
Table 5 Frequency of all applied treatments in eyes with severe 
chronic central serous chorioretinopathy
Treatment modality Frequency and 
specifications
Mean number of treatments per case (range) 2.4 (1–20)
number of untreated cases, n (%) 25 (14)
Total number of PDTs, n (%) 246 (60)
successfula PDT, n (%) 153 (62)
PDT modality, n (%) 6 (2) full settings
160 (66) half-dose
39 (16) half-time
6 (2) half-fluency
35 (14) unknown
PDT spot size in µm (range) 4,457 (1,000–8,800)b
Total number of sMls, n (%) 81 (20)
successfula sMls, n (%) 7 (9)
Total number of conventional thermal laser 
treatments
84 (20)
successfula conventional thermal laser 
treatments, n (%)
54 (64)
Notes: aSuccessful treatment was defined by a complete resolution of subretinal 
fluid and/or disappearance of posterior cystoid retinal degeneration. ban average 
size is reported in case multiple PDT spots were used.
Abbreviations: PDT, photodynamic therapy; sMl, subthreshold micropulse diode 
laser.
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a chronic course are generally agreed upon.10 These general 
clinical characteristics of chronicity include $1 significant 
multifocal areas of atrophic RPE alterations and/or multifocal 
areas of leakage. Nevertheless, various clinical presentations 
exist within cCSC, ranging from mild to severe manifesta-
tions with clinical characteristics as described here. There-
fore, the diagnosis and treatment decision making may form 
a challenging task in daily clinical practice when confronted 
with the clinical spectrum of CSC.
In the present study, only 14% of the severe cCSC patients 
had a history of documented acute CSC. Otsuka et al14 
reported a larger incidence of previous acute episodes (36% 
in 25 severe cCSC cases) as compared to the present study, 
whereas Yannuzzi et al20 reported that merely 8% of 25 cCSC 
patients in their study had previously experienced an acute 
CSC episode. Therefore, these observations at least indicate 
that a well observed, clinical episode of acute CSC is not 
required to evolve to chronicity in CSC and to develop exten-
sive, severe cCSC. Since 73% of the studied eyes showed 
signs of chronicity at first presentation, it is conceivable that 
chronic choroidal leakage and congestion may cause gradual, 
subclinical damage to the overlying RPE. This may explain 
why most severe cCSC cases in our cohort showed pre-
existing signs of long-standing disease at first presentation. 
We also observed that the area of choroidal hyperpermeability 
on ICGA was larger than the area of leakage on FA in most 
cases. This can also be an indication of a more widespread 
underlying choroidal disease process that is slumbering and 
gradually damaging the RPE. This process may have started 
subclinically and without patients notification. Only when 
there is a RPE outer blood-retinal barrier breakdown with 
SRF accumulation the vision loss may occur. The multifocal 
and/or diffuse leakage on FA in some severe cCSC cases can 
be considered as the “tip of the iceberg” of a larger underly-
ing area of dysfunctional leaking choroid. Eventually, focal 
and/or diffuse damage to the RPE and the outer blood–retinal 
barrier can result in more pronounced damage to the overlying 
neuroretina, for instance, through the development of RPE 
atrophy, SRF accumulation, and PCRD.
In the present study, final visual outcome was most 
strongly correlated with baseline BCVA (before severe 
presentation), location of DARA within 1 DD from the 
fovea, and DARA surface size. Despite a high percentage 
of post-treatment SRF resolution in most cases (76%), final 
visual outcome did not improve significantly in our cohort. 
The BCVA at final visit was on average 70 ETDRS letters. 
In another smaller study, including patients with presumably 
severe disease, a final BCVA of .0.5 Snellen (70 ETDRS 
letters) was reported in 80% of the eyes (37/46).14 Wang 
et al21 have postulated that SRF leakage lasting .4 months 
may cause retinal atrophy and irreversible visual loss, but 
little is known about the exact time that has to ensue before 
chronic SRF accumulation causes photoreceptor degenera-
tion, neuroretinal atrophy, and consequent vision loss. In the 
present study, most cases had a disease duration that was far 
longer than 4 months and experienced multiple recurrences 
of SRF accumulation. It is therefore plausible to assume that 
irreversible macular photoreceptor dysfunction due to pro-
longed disease has contributed to irreversible BCVA loss.
In this study, DARA was the most prevalent finding 
among severely affected patients, and DARA surface also 
tended to expand over time. The development of diffuse 
RPE atrophy has been related to corticosteroid use.22 In the 
present cohort, 18% of the patients reported corticosteroid 
use. However, we did not observe a significant negative cor-
relation between corticosteroid use and a poor post-treatment 
BCVA, confirming our earlier findings in patients with 
steroid-associated cCSC who were treated with PDT.23
Among our studied cases, the majority (87%) was treated 
during follow-up. Nevertheless, SRF persisted in 24% of 
cases, and PCRD remained in 18% until final visit. Silva et al24 
previously reported a 93% SRF resolution and a 100% post-
treatment PCRD resolution in a cohort of 46 general cCSC 
cases. It has been previously suggested that outer retinal 
ischemia due to chronic retinal detachment may contribute to 
PCRD development.25,26 Despite increasing evidence on the 
superiority of PDT as first-choice treatment for CSC, a large 
variability in CSC treatment exists in clinical practice.27,28 
In this study, PDT with reduced settings was the most com-
monly used treatment modality, with the highest success rate 
(62%) in resolution of SRF and PCRD. This success rate is 
lower when compared to literature on outcome of PDT in a 
general cCSC population,29–31 which may be related to the 
disease severity as well as our strict definition of success: a 
complete resolution of SRF and PCRD.
In the present study, we proposed a definition for sever-
ity in cCSC. The choice of the suggested criteria such as a 
large cumulative surface of DARA in the macula of .5 DD 
was somewhat arbitrary, based on clinical experience of the 
involved retina specialists. Future research must establish 
the validity of these criteria of severity. In order to report 
a history of acute CSC in this retrospective study, we were 
dependent on symptomatic disease episodes. Therefore, the 
abovementioned percentage of patients with a history of 
acute CSC may be an underestimation, since a small propor-
tion of acute CSC episodes may occur asymptomatically. 
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severe phenotypes of cCsC
Here, we could demonstrate that patient characteristics 
including baseline BCVA, total area of DARA, location of 
DARA, and presence of PCRD can predict up to 47% of the 
variance in final BCVA outcome in severe cCSCs. Future 
prospective studies may provide additional information on 
the retinal and choroidal vasculature conditions and reveal 
other prognostic factors associated with progression and 
visual outcome in cCSC.
Conclusion
Based on the suggested definition in this study, CSC appears 
to encompass a clinical spectrum that includes a group of 
severe cases of cCSC which often respond to treatment, but 
with a more guarded visual prognosis as compared to cCSC 
cases without characteristics of severity. Most of these severe 
cCSC cases already have a chronic phenotype at presentation, 
whereas only a minority of them have a documented history 
of acute CSC. This may indicate that acute CSC and (severe) 
cCSC are relatively distinct phenotypes both clinically and 
pathophysiologically. Future studies can be directed toward 
a further distinction of different phenotypes within the CSC 
spectrum, to gain further insight into possible differences in 
genetic background, pathophysiology, optimal treatments, 
and treatment outcome.
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